Spotify Challenges YouTube, Adds Video Support For All Platform Podcasters
Spotify adds video support for all users in latest move to capture market share. Over 250,000 video podcasts now on platform, up from 100,000 in 2023.
Quad Witching Driving AI Stocks Including Nvidia Higher, More One Month Lows Than Highs In NASDAQ
To gain an edge, this is what you need to know today.
Summer Solstice Blues: Market Has History Of Underperforming On Longest Day Of The Year
Summer solstice, the year's longest day, usually sees S&P 500 fall. In the last 10 yrs, it dropped on 6 out of 7 times. But there's an exception
Microsoft Fights To Reclaim The Top Spot As Nvidia’s Stock Split Catapults Them To Claim the Crown As The World’s Most Valuable Company
Nvidia has overtaken Microsoft and Apple to become the world's most valuable publicly traded company.
Microsoft has experienced an 18% increase year-to-date, indicating potential for future growth.
How Apple’s 825% Decade-Long Growth Is Accelerating With Its New AI Platform Transforming Tech And Boosting Its Stock Performance
The market has responded favorably to Apple's new AI initiatives, with financial analysts upgrading Apple's stock to "Buy".
After the WWDC announcement, Apple's stock price increased by over 7%, surpassing $200.
Nvidia’s Rise To Surpass Microsoft And Apple As World’s Most Valuable Company Linked To ‘Once-In-A-Generation Multi-Purpose Technological Transformation,’ Says Mohamed El-Erian
Noted economist Mohamed El-Erian recently took to X, formerly Twitter, to acknowledge the extraordinary rise of Nvidia Corp.…
A Leading Tech ETF Is Shifting The Balance From Apple To Nvidia With A Massive $23 Billion Stake Exchange As Nvidia’s Stock Skyrockets By 164%
A major technology ETF is set to undergo a significant rebalance, increasing its Nvidia holdings from 6% to 21%.
This strategic reallocation will involve purchasing approximately $11 billion worth of Nvidia shares.
Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its blockbuster cancer drug Imfinzi combined with chemotherapy being used as a treatment forpatients suffering from specific type of endometrial cancer.
Betting On A Stock That Plummeted Post-Earnings: Trying To Avoid Repeating Two Big Mistakes
The Risk Of Buying After A Post-Earnings Drop